Huang et al. [84] found that tumorigenesis and cancer stem cell (CSC) self-renewal in ovarian cancer were both suppressed by FTO treatment, which is the first study to link FTO to the cell regulatory process mediated by the second messenger cyclic adenosine monophosphate (cAMP). The gene discussed is FTO; the disease is ovarian carcinoma.